GÜVEN, D. C. Et Al. 2021. Poorer baseline performance status is associated with increased thromboembolism risk in metastatic cancer patients treated with immunotherapy. Supportive Care in Cancer , vol.29, no.9 , 5417-5423.

GÜVEN, D. C., Aksun, M. S., Sahin, T. K., AKTEPE, O. H., Yildirim, H. C., Taban, H., ... Ceylan, F.(2021). Poorer baseline performance status is associated with increased thromboembolism risk in metastatic cancer patients treated with immunotherapy. Supportive Care in Cancer , vol.29, no.9, 5417-5423.

GÜVEN, DENİZ Et Al. "Poorer baseline performance status is associated with increased thromboembolism risk in metastatic cancer patients treated with immunotherapy," Supportive Care in Cancer , vol.29, no.9, 5417-5423, 2021

GÜVEN, DENİZ C. Et Al. "Poorer baseline performance status is associated with increased thromboembolism risk in metastatic cancer patients treated with immunotherapy." Supportive Care in Cancer , vol.29, no.9, pp.5417-5423, 2021

GÜVEN, D. C. Et Al. (2021) . "Poorer baseline performance status is associated with increased thromboembolism risk in metastatic cancer patients treated with immunotherapy." Supportive Care in Cancer , vol.29, no.9, pp.5417-5423.

@article{article, author={DENİZ CAN GÜVEN Et Al. }, title={Poorer baseline performance status is associated with increased thromboembolism risk in metastatic cancer patients treated with immunotherapy}, journal={Supportive Care in Cancer}, year=2021, pages={5417-5423} }